+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "CAR T Cell"

Targeted Immunotherapy in Oncology - Product Thumbnail Image

Targeted Immunotherapy in Oncology

  • Report
  • November 2021
  • 106 Pages
  • Global
From
Novel Therapeutic Approaches for Treatment of Cancer - Product Thumbnail Image

Novel Therapeutic Approaches for Treatment of Cancer

  • Report
  • July 2018
  • 15 Pages
  • Global
From
From
From
From
CAR T - Cell Therapy - Competitive landscape, 2023 - Product Thumbnail Image

CAR T - Cell Therapy - Competitive landscape, 2023

  • Report
  • April 2023
  • 500 Pages
  • Global
From
Oncolytic Virus - Competitive Landscape, 2022 - Product Thumbnail Image

Oncolytic Virus - Competitive Landscape, 2022

  • Report
  • October 2022
  • 300 Pages
  • Global
From
From
From
From
From
From
From
Car T-Cell Therapy for Multiple Myeloma - Pipleine Insight, 2021 - Product Thumbnail Image

Car T-Cell Therapy for Multiple Myeloma - Pipleine Insight, 2021

  • Clinical Trials
  • September 2021
  • 60 Pages
  • Global
From
From
From
Loading Indicator

CAR T Cell therapy is a type of immunotherapy used to treat certain types of cancer. It is a type of gene therapy that uses a patient's own immune cells to recognize and attack cancer cells. The patient's T cells are collected and modified to express a chimeric antigen receptor (CAR) that binds to a specific antigen on the surface of the cancer cells. The modified T cells are then infused back into the patient, where they can recognize and attack the cancer cells. CAR T Cell therapy has been approved for the treatment of certain types of blood cancers, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). It is also being studied for the treatment of other types of cancer, including solid tumors. CAR T Cell therapy is a rapidly growing field, with many companies developing and marketing products. Some of the major players in the market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Cellectis. Show Less Read more